Q-omics provides the consensus-scored PTP4A2P1 profile across patient tissues and cancer cell-line models. PTP4A2P1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PTP4A2P1 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, PTP4A2P1 RNA expression shows 17,434 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KIRP, and UVM as cancer lineages where PTP4A2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTP4A2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTP4A2P1 survival associations across molecular data types. PTP4A2P1 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTP4A2P1 RNA expression–survival associations across cancer types. High PTP4A2P1 expression shows unfavorable associations in KIRC, ACC, KIRP, ESCA and KICH, but favorable associations in COAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PTP4A2P1 RNA expression.
This table summarizes PTP4A2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for PTP4A2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTP4A2P1 shows lower tumor expression in BRCA and KICH and higher tumor expression in KIRP, LIHC, LUAD and HNSC. The KIRP box plot shows higher PTP4A2P1 RNA expression in tumor versus normal tissue (log2 FC = +0.710, t-test p < 0.001).
This table shows molecular features associated with PTP4A2P1 in patient tissues and cancer cell lines. In patient samples, PTP4A2P1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
